Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...

Learn more about whether Gilead Sciences, Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corp. (SCHW), ...

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...

Lenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

David Furnish’s leadership at EJAF proves brands can do more than raise awareness —they can dismantle stigma and drive ...

Salesforce's outlook fell short of analysts’ expectations, sending shares lower in extended trading Wednesday.

Assembly Bio said that it plans to advance ABI-1179 directly into the Phase 1b portion of the study, which will include ...